Two Glycoproteins of Hendra Virus (HeV)

HeV contains two surface glycoproteins: fusion protein (F) and adhesion protein (G). Both proteins help the virus to enter the cell and also induce the production of neutralizing antibodies. The function of G protein is responsible for the adhesion between the cell and the virus. Soluble G proteins play a key role in the study of viral receptors. F proteins are important for virus-mediated cell fusion. G and F proteins protrude on the envelope surface and bind to receptors on the surface of the target cell. They are the main functional proteins of viruses for cell fusion and adhesion. They are also target proteins for vaccine development. Some studies on F and G protein vaccines have been reported.

HeV Vaccine Development Service at CD BioGlyco

CD BioGlyco is experienced in subunit Vaccine Development. Current HeV vaccine research is focused on F and G proteins, including viral vector vaccines, Recombinant Subunit Vaccines, virus-like particle vaccines, etc. We provide HeV recombinant protein subunit vaccine development services.

We design protein vaccines through immunoinformatics. After that, we use recombinant DNA technology to construct recombinant plasmids encoding G proteins and fusions with other genes. We then transfer the recombinant plasmid to prokaryotic or baculovirus expression systems for expression. To obtain a purer target protein, we also need to establish a purification process for the target protein. We will choose nickel column affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration chromatography, etc., according to the protein characteristics. Recombinant subunit vaccines have a good safety profile. An additional immune Adjuvant is needed to enhance its immunogenicity. We will screen the immunoadjuvants or immunoenhancers with better immunoenhancement effects. Finally, we will test the purity, immunogenicity, and activity of the produced protein. Our vaccine evaluation system is well established. Both in vitro and in vivo testing can be done.

Fig.1 One-stop vaccine development process. (CD BioGlyco)

Applications

• Our HeV vaccine development services include the production of recombinant F and G proteins that can be used in the development of Hev assays.
• Monoclonal antibodies are widely characterized by high specificity and sensitivity and are used in the immunological identification of pathogens and their specific antibodies. Our recombinant F and G proteins play an important role in the production of monoclonal antibodies.

Advantages of Us

• The purity of proteins we produce by various expression systems is verified by SDS-PAGE and MALS, with high activity and high immunogenicity.
• Compared to other vaccines such as viral vector vaccines and virus-like particle vaccines, the subunit vaccines we develop are suitable for people with weakened immune systems, have long-term immunity, and are relatively safe.
• When selecting expression systems for vaccine production, we consider the impact of multiple factors on vaccine antigen expression, including expression levels, the presence of post-translational modifications, etc.

CD BioGlyco has been working for many years on the development of a wide range of new vaccines against viral diseases. In addition to the HeV vaccine, we also develop Ebola Virus Vaccine, Hepatitis C Virus Vaccine, etc. Please feel free to contact us to tell us about your needs. Our professional vaccine development team will give you full support.

Reference

1. Pallister, J.; et al. A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine. 2011, 29(34): 5623-5630.